| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| ACCOUNTING FEES | 3,400 | 0 | 0 |
| Description of Property | Date Acquired | Cost or Other Basis | Prior Years' Depreciation | Computation Method | Rate / Life (# of years) |
Current Year's Depreciation Expense | Net Investment Income | Adjusted Net Income | Cost of Goods Sold Not Included |
|---|---|---|---|---|---|---|---|---|---|
| LEASEHOLD IMPROVEMENTS | 2013-12-31 | 15,596 | 4,400 | SL | 39.000000000000 | 400 | 0 | ||
| FURNITURE & EQUIPMENT | 2013-12-31 | 14,596 | 14,596 | SL | 7.000000000000 | 0 | 0 | ||
| WEBSITE DEVELOPMENT | 2018-04-02 | 4,740 | 1,817 | SL | 15.000000000000 | 316 | 0 |
| Identifier | Return Reference | Explanation |
|---|---|---|
| FORM 8886 (1 OF 3), LINE 7(E) | (CONTINUED)REPORTED HEREIN HAVE OCCURRED THROUGHOUT THE YEAR AS PART OF THIS REGULAR ACTIVITY AND PURSUANT TO THIS SAME PURPOSE. FOR FINANCIAL ACCOUNTING PURPOSES, THE TRANSACTION IS BEING ACCOUNTED FOR IN ACCORDANCE WITH U.S. GAAP.THE ADJUSTED TAX BASIS WAS DETERMINED BY WAY OF THE CASH PAID AND HAS BEEN ADJUSTED BY THE APPLICATION OF THE WASH SALE PROVISIONS UNDER SECTION 1091; CONSTRUCTIVE SALES PROVISIONS UNDER SECTION 1259; STRADDLE LOSS DEFERRALS UNDER SECTION 1092; BASIS ADJUSTMENTS UNDER SECTION 754; AND/OR BY OTHER STATUTORY PROVISIONS.THE SALE OF THESE ASSETS RESULTED IN A SECTION 165 LOSS WHICH EXCEEDS THE RELEVANT $2,000,000 REPORTABLE LOSS THRESHOLD. THE TRANSACTION IS BEING REPORTED SINCE IT DOES NOT MEET ANY OF THE SPECIFIED EXCEPTIONS PROVIDED IN REV. PROC. 2013-11.NAME OF SECURITY SOLD: IMMPACT BIO USA, INC. - EQUITYDATE OF PURCHASE: VARIOUSDATE OF SALE: 10/31/2024CASH RECEIVED: 3,419ORIGINAL COST BASIS: 4,817BASIS ADJUSTMENT: -AMOUNT OF SECTION 165 LOSS: (1,398)NAME OF SECURITY SOLD: THESEUS PHARMACEUTICALS INC - EQUITYDATE OF PURCHASE: VARIOUSDATE OF SALE: 2/15/2024CASH RECEIVED: 3,693ORIGINAL COST BASIS: 7,517BASIS ADJUSTMENT: -AMOUNT OF SECTION 165 LOSS: (3,824)NAME OF SECURITY SOLD: KINNATE BIOPHARMA INC. - EQUITYDATE OF PURCHASE: VARIOUSDATE OF SALE: 4/2/2024CASH RECEIVED: 887ORIGINAL COST BASIS: 3,370BASIS ADJUSTMENT: -AMOUNT OF SECTION 165 LOSS: (2,483) | |
| FORM 8886 (2 OF 3), LINE 7(E) | (CONTINUED)THE ACQUISITION AND DISPOSITIONS OF SUCH PARTNERSHIP INTERESTS. THE LOSS REPORTED HEREIN HAS RESULTED AS PART OF THIS REGULAR ACTIVITY AND PURSUANT TO THIS SAME PURPOSE. FOR FINANCIAL ACCOUNTING PURPOSES, THE TRANSACTION IS BEING ACCOUNTED FOR IN ACCORDANCE WITH U.S. GAAP.ON VARIOUS DATES, THE FUND MADE INVESTMENTS IN SERANDITE GEM INVESTMENTS LTD. ("PARTNERSHIP"). THE FUND BECAME A PARTNER IN THE PARTNERSHIP AT THAT DATE. THE FUND DISPOSED OF ITS INVESTMENT IN THE PARTNERSHIP ON 11/15/2024. DURING THE PERIOD AFTER THE INITIAL INVESTMENT IN THE PARTNERSHIP IN 2021 THROUGH THE CURRENT TAX YEAR, THE FUNDS TAX BASIS IN SERANDITE GEM INVESTMENTS LTD. WAS INCREASED BY CAPITAL CONTRIBUTIONS AS WELL AS TAXABLE INCOME ALLOCATED TO THE FUND FROM THE PARTNERSHIP. DURING THE SAME PERIOD, THE FUNDS TAX BASIS IN SERANDITE GEM INVESTMENTS LTD. WAS DECREASED BY CASH DISTRIBUTED TO THE FUND AS WELL AS TAXABLE LOSSES AND DEDUCTIONS ALLOCATION TO THE FUND FROM THE PARTNERSHIP.THE DISPOSITION OF THIS INVESTMENT RESULTED IN A SECTION 165 LOSS WHICH EXCEEDS THE RELEVANT $2,000,000 REPORTABLE LOSS THRESHOLD. THE TRANSACTION IS BEING REPORTED SINCE IT DOES NOT MEET ANY OF THE SPECIFIED EXCEPTIONS PROVIDED IN REV. PROC. 2013-11.CASH RECEIVED: -COST BASIS: $ 993NET TAX ADJUSTMENT TO BASIS: -AMOUNT OF SECTION 165 LOSS: $ (993) | |
| FORM 8886 (3 OF 3), LINE 7(E) | (CONTINUED)OCCURRED THROUGHOUT THE YEAR AS PART OF THIS REGULAR ACTIVITY AND PURSUANT TO THIS SAME PURPOSE. FOR FINANCIAL ACCOUNTING PURPOSES, THE TRANSACTION IS BEING ACCOUNTED FOR IN ACCORDANCE WITH U.S. GAAP.THE ADJUSTED TAX BASIS WAS DETERMINED BY WAY OF THE CASH PAID AND HAS BEEN ADJUSTED BY THE APPLICATION OF THE WASH SALE PROVISIONS UNDER SECTION 1091; CONSTRUCTIVE SALES PROVISIONS UNDER SECTION 1259; STRADDLE LOSS DEFERRALS UNDER SECTION 1092; BASIS ADJUSTMENTS UNDER SECTION 754; AND/OR BY OTHER STATUTORY PROVISIONS.THE SALE OF THESE ASSETS RESULTED IN A SECTION 165 LOSS WHICH EXCEEDS THE RELEVANT $2,000,000 REPORTABLE LOSS THRESHOLD. THE TRANSACTION IS BEING REPORTED SINCE IT DOES NOT MEET ANY OF THE SPECIFIED EXCEPTIONS PROVIDED IN REV. PROC. 2013-11.NAME OF SECURITY SOLD: IMMPACT BIO USA, INC. - EQUITYDATE OF PURCHASE: VARIOUSDATE OF SALE: 10/31/2024CASH RECEIVED: 8,664ORIGINAL COST BASIS: 12,207BASIS ADJUSTMENT: -AMOUNT OF SECTION 165 LOSS: (3,543)NAME OF SECURITY SOLD: KINNATE BIOPHARMA INC. - EQUITYDATE OF PURCHASE: VARIOUSDATE OF SALE: 04/02/2024CASH RECEIVED: 5,651ORIGINAL COST BASIS: 15,650BASIS ADJUSTMENT: -AMOUNT OF SECTION 165 LOSS: (9,999)NAME OF SECURITY SOLD: THESEUS PHARMACEUTICALS INC - EQUITYDATE OF PURCHASE: VARIOUSDATE OF SALE: 02/15/2024CASH RECEIVED: 10,306ORIGINAL COST BASIS: 25,864BASIS ADJUSTMENT: -AMOUNT OF SECTION 165 LOSS: (15,558) |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| INVESTMENTS - OTHER | AT COST | 17,938,082 | 21,746,333 |
| Category / Item | Cost / Other Basis | Accumulated Depreciation | Book Value | End of Year Fair Market Value |
|---|---|---|---|---|
| LEASEHOLD IMPROVEMENTS | 15,596 | 4,800 | 10,796 | |
| FURNITURE & EQUIPMENT | 14,596 | 14,596 | 0 | |
| WEBSITE DEVELOPMENT | 4,740 | 2,133 | 2,607 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| OFFICE SUPPLIES | 68 | 0 | 0 | |
| PRIOR PERIOD ADJUSTMENTS | 280 | 280 | 0 | |
| UTILITIES | 1,366 | 0 | 0 | |
| POSTAGE | 58 | 0 | 0 | |
| BUSINESS LICENSES | 21 | 0 | 0 | |
| DUES & SUBSCRIPTIONS | 1,940 | 0 | 0 | |
| ADMINISTRATIVE FEES | 20,000 | 20,000 | 0 | |
| MEALS & ENTERTAINMENT | 130 | 0 | 0 | |
| PENALTIES AND INTEREST | 46 | 0 | 0 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| OTHER INCOME - NORTHERN | 1,517 | 1,517 | 1,517 |
| OTHER INCOME - PASSTHROUGH | 227,121 | 226,464 | 227,121 |
| OTHER UNRELATED INCOME - PASSTHROUGH | 657 | 657 | 657 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| BANK FEES | 6 | 6 | 0 | |
| CUSTODY FEES | 7,248 | 7,248 | 0 | |
| CONSULTING FEES | 20,000 | 20,000 | 0 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FOREIGN | 116 | 116 | 0 | |
| FOREIGN PASSTHROUGH | 836 | 836 | 0 | |
| STATE | 41 | 41 | 0 | |
| PAYROLL TAXES | 7,392 | 74 | 7,318 |